Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp (NQ: LEXX )

2.100 +0.010 (+0.48%)
Streaming Delayed Price Updated: 12:42 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lexaria Bioscience Corp

< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
KELOWNA, BC / ACCESSWIRE / December 16, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.
Kelowna, British Columbia – TheNewswire - December 16, 2021 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms... 
Via TheNewswire.com
Lexaria Bioscience Committed to Innovation and Improving Quality of Life
Lexaria presented at this year’s Benzinga Global Small Cap Conference held on December 8-9, 2021 The event came right after the company announced human clinical... 
Via Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Committed to Innovation and Improving Quality of Life
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Participates in the Benzinga Global Small Cap Conference; Committed to Innovation and Improving Quality of Life
Via Investor Brand Network
Why Lexaria Shares Are Rising Today
Lexaria Bioscience Corp (NASDAQ:LEXX) is trading higher We... 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Study Results Expected to Demonstrate DehydraTECH-CBD’s Effectiveness Against Hypertension
Via Investor Brand Network
Exposures Product Safety
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Study Results Expected to Demonstrate DehydraTECH-CBD’s Effectiveness Against Hypertension
Via CannabisNewsWire
Exposures Product Safety
Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion
KELOWNA, BC / ACCESSWIRE / December 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its human... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria's Upcoming R&D Programs Targeting Global Markets Exceeding $160B
Lexaria Bioscience plans to launch approximately 12 applied research and development programs in 2022 The programs are designed to explore the ability of the company’s... 
Via Benzinga
Lexaria’s (NASDAQ: LEXX) Upcoming R&D Programs Targeting Global Markets Exceeding $160B
Via Investor Brand Network
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Upcoming R&D Programs Targeting Global Markets Totaling Over $160 Billion
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Reshape Lifesciences (NASDAQ:RSLS... 
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals and Therapeutics
Via CannabisNewsWire
52 Biggest Movers From Yesterday
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares surged 84.1% to close at $19.11 on Wednesday. Insignia Systems recently announced the commencement of a formal process to... 
Via Benzinga
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals and Therapeutics
Via Investor Brand Network
Lexaria Bioscience Featured in Virtual Coverage of Benzinga's Small Cap Conference
Lexaria Bioscience (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company leverages its patented technology, DehydraTECH(TM), to improve the delivery of... 
Via Benzinga
35 Stocks Moving In Wednesday's Mid-Day Session
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 79% to $18.63. Insignia Systems recently announced the commencement of a formal process to explore strategic options... 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Follow-Up Study Results Confirming DehydraTECH(TM)-CBD Arterial Stiffness Reduction
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Follow-Up Study Results Confirming DehydraTECH(TM)-CBD Arterial Stiffness Reduction
Via Investor Brand Network
Read Why Lexaria Bioscience Shares Are Surging During Wednesday Premarket?
Lexaria Bioscience Corp (NASDAQ: LEXX) has issued follow-up results from human clinical study HYPER-H21-2 of DehydraTECH-processed cannabidiol (CBD). The data... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Lexaria Bioscience (NASDAQ:LEXX) shares increased by 30.28% to $6.41 during Wednesday's pre-market session. The company's market cap stands at $36.7... 
Via Benzinga
Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2
Results suggest broader applications for DehydraTECH-CBD beyond hypertension KELOWNA, BC / ACCESSWIRE / December 8, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in Virtual Coverage of Benzinga’s Small Cap Conference
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Participate in Upcoming Benzinga Global Small Cap Conference
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Participate in Upcoming Benzinga Global Small Cap Conference
Via Investor Brand Network
Lexaria Bioscience Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD
Lexaria Bioscience Corp. (NASDAQ: 
Via Benzinga
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD
Via Investor Brand Network
Lexaria's DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study
Lexaria Bioscience Corp 
Via Benzinga
< Previous 1 2
...
23 24 25 26 27 28 29 30 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS